Publicaties over renale denervatie

1: Sanders MF, Reitsma JB, Morpey M, Gremmels H, Bots ML, Pisano A, Bolignano D,

Zoccali C, Blankestijn PJ. Renal safety of catheter-based renal denervation:

systematic review and meta-analysis. Nephrol Dial Transplant. 2017 Sep

1;32(9):1440-1447. doi: 10.1093/ndt/gfx088. PubMed PMID: 29059396.

 

 

2: Persu A, Gordin D, Jacobs L, Thijs L, Bots ML, Spiering W, Miroslawska A,

Spaak J, Rosa J, de Jong MR, Berra E, Fadl Elmula FEM, Wuerzner G, Taylor AHM,

Olszanecka A, Czarnecka D, Mark PB, Burnier M, Renkin J, Kjeldsen SE, Widimský J,

Elvan A, Kahan T, Steigen TK, Blankestijn PJ, Tikkanen I, Staessen JA; European

Network COordinating research on Renal Denervation (ENCOReD). Blood pressure

response to renal denervation is correlated with baseline blood pressure

variability: a patient-level meta-analysis. J Hypertens. 2017 Oct 16. doi:

10.1097/HJH.0000000000001582. [Epub ahead of print] PubMed PMID: 29045339.

 

 

3: de Beus E, de Jager RL, Beeftink MM, Sanders MF, Spiering W, Vonken EJ,

Voskuil M, Bots ML, Blankestijn PJ; SYMPATHY study group. Salt intake and blood

pressure response to percutaneous renal denervation in resistant hypertension. J

Clin Hypertens (Greenwich). 2017 Nov;19(11):1125-1133. doi: 10.1111/jch.13085.

Epub 2017 Sep 19. PubMed PMID: 28929577.

 

 

4: de Jager RL, van Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY

investigators. Medication adherence in patients with apparent resistant

hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018

Jan;84(1):18-24. doi: 10.1111/bcp.13402. Epub 2017 Oct 10. PubMed PMID: 28815689;

PubMed Central PMCID: PMC5736834.

 

 

5: Blankestijn PJ. Does renal denervation lower sympathetic activity? Nephrol

Dial Transplant. 2017 Aug 1;32(8):1265-1267. doi: 10.1093/ndt/gfx217. PubMed

PMID: 28810725.

 

 

6: de Jager RL, Casteleijn NF, de Beus E, Bots ML, Vonken EE, Gansevoort RT,

Blankestijn PJ. Catheter-based renal denervation as therapy for chronic severe

kidney-related pain. Nephrol Dial Transplant. 2017 Jun 22. doi:

10.1093/ndt/gfx086. [Epub ahead of print] PubMed PMID: 28645206.

 

 

7: Beeftink MM, Spiering W, De Jong MR, Doevendans PA, Blankestijn PJ, Elvan A,

Heeg JE, Bots ML, Voskuil M. Renal denervation beyond the bifurcation: The effect

of distal ablation placement on safety and blood pressure. J Clin Hypertens

(Greenwich). 2017 Apr;19(4):371-378. doi: 10.1111/jch.12989. Epub 2017 Mar 14.

PubMed PMID: 28296025.

 

 

8: Sanders MF, van Doormaal PJ, Beeftink MMA, Bots ML, Fadl Elmula FEM, Habets J,

Hammer F, Hoffmann P, Jacobs L, Mark PB, Persu A, Renkin J, Roditi G, Spiering W,

Staessen JA, Taylor AH, Verloop WL, Vink EE, Vonken EJ, Voskuil M, Leiner T,

Blankestijn PJ; European Network COordinating research on Renal Denervation

(ENCOReD) Consortium. Renal artery and parenchymal changes after renal

denervation: assessment by magnetic resonance angiography. Eur Radiol. 2017

Sep;27(9):3934-3941. doi: 10.1007/s00330-017-4770-7. Epub 2017 Mar 7. PubMed

PMID: 28271154; PubMed Central PMCID: PMC5544801.

 

 

9: de Jager RL, de Beus E, Beeftink MM, Sanders MF, Vonken EJ, Voskuil M, van

Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY Investigators. Impact of

Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial.

Hypertension. 2017 Apr;69(4):678-684. doi: 10.1161/HYPERTENSIONAHA.116.08818.

PubMed PMID: 28264922.

 

 

10: Casteleijn NF, van Gastel MD, Blankestijn PJ, Drenth JP, de Jager RL,

Leliveld AM, Stellema R, Wolff AP, Groen GJ, Gansevoort RT; DIPAK Consortium.

Novel treatment protocol for ameliorating refractory, chronic pain in patients

with autosomal dominant polycystic kidney disease. Kidney Int. 2017

Apr;91(4):972-981. doi: 10.1016/j.kint.2016.12.007. Epub 2017 Jan 31. PubMed

PMID: 28159317.

 

 

11: Blankestijn PJ, Bots ML. [Renal denervation as treatment option for

hypertension]. Ned Tijdschr Geneeskd. 2016;160(0):D629. Dutch. PubMed PMID:

27781967.

 

 

12: Beeftink MM, Spiering W, Bots ML, Verloop WL, De Jager RL, Sanders MF, Vonken

EJ, Blankestijn PJ, Voskuil M. Renal Denervation in a Real Life Setting: A

Gradual Decrease in Home Blood Pressure. PLoS One. 2016 Sep 15;11(9):e0162251.

doi: 10.1371/journal.pone.0162251. eCollection 2016. PubMed PMID: 27631608;

PubMed Central PMCID: PMC5025101.

 

 

13: Ewen S, Ukena C, Lüscher TF, Bergmann M, Blankestijn PJ, Blessing E, Cremers

B, Dörr O, Hering D, Kaiser L, Nef H, Noory E, Schlaich M, Sharif F, Sudano I,

Vogel B, Voskuil M, Zeller T, Tzafriri AR, Edelman ER, Lauder L, Scheller B, Böhm

M, Mahfoud F. Anatomical and procedural determinants of catheter-based renal

denervation. Cardiovasc Revasc Med. 2016 Oct - Nov;17(7):474-479. doi:

10.1016/j.carrev.2016.08.004. Epub 2016 Aug 20. PubMed PMID: 27617388.

 

 

 

14: Sanders MF, Blankestijn PJ. Chronic Kidney Disease As a Potential Indication

for Renal Denervation. Front Physiol. 2016 Jun 8;7:220. doi:

10.3389/fphys.2016.00220. eCollection 2016. Review. PubMed PMID: 27375498; PubMed

Central PMCID: PMC4896963.

 

 

15: De Jager RL, Sanders MF, Bots ML, Lobo MD, Ewen S, Beeftink MM, Böhm M,

Daemen J, Dörr O, Hering D, Mahfoud F, Nef H, Ott C, Saxena M, Schmieder RE,

Schlaich MP, Spiering W, Tonino PA, Verloop WL, Vink EE, Vonken EJ, Voskuil M,

Worthley SG, Blankestijn PJ. Renal denervation in hypertensive patients not on

blood pressure lowering drugs. Clin Res Cardiol. 2016 Sep;105(9):755-62. doi:

10.1007/s00392-016-0984-y. Epub 2016 Apr 22. PubMed PMID: 27105858; PubMed

Central PMCID: PMC4989018.

 

 

16: Sanders MF, Blankestijn PJ, Voskuil M, Spiering W, Vonken EJ, Rotmans JI, van

der Hoeven BL, Daemen J, van den Meiracker AH, Kroon AA, de Haan MW, Das M, Bax

M, van der Meer IM, van Overhagen H, van den Born BJ, van Brussel PM, van der

Valk PH, Smak Gregoor PJ, Meuwissen M, Gomes ME, Oude Ophuis T, Troe E, Tonino

WA, Konings CJ, de Vries PA, van Balen A, Heeg JE, Smit JJ, Elvan A, Steggerda R,

Niamut SM, Peels JO, de Swart JB, Wardeh AJ, Groeneveld JH, van der Linden E,

Hemmelder MH, Folkeringa R, Stoel MG, Kant GD, Herrman JP, van Wissen S, Deinum

J, Westra SW, Aengevaeren WR, Parlevliet KJ, Schramm A, Jessurun GA, Rensing BJ,

Winkens MH, Wierema TK, Santegoets E, Lipsic E, Houwerzijl E, Kater M, Allaart

CP, Nap A, Bots ML. Safety and long-term effects of renal denervation: Rationale

and design of the Dutch registry. Neth J Med. 2016 Jan;74(1):5-15. PubMed PMID:

26819356.

 

 

17: van Amsterdam WA, Blankestijn PJ, Goldschmeding R, Bleys RL. The

morphological substrate for Renal Denervation: Nerve distribution patterns and

parasympathetic nerves. A post-mortem histological study. Ann Anat. 2016

Mar;204:71-9. doi: 10.1016/j.aanat.2015.11.004. Epub 2015 Nov 23. PubMed PMID:

26617159.

 

 

 

18: Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K,

Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner

M, Kjeldsen SE, Lüscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L,

Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, Wijns W,

Zeller T, Schmieder RE. Proceedings from the European clinical consensus

conference for renal denervation: considerations on future clinical trial design.

Eur Heart J. 2015 Sep 1;36(33):2219-27. doi: 10.1093/eurheartj/ehv192. Epub 2015

May 18. PubMed PMID: 25990344.

 

 

 

 

19: Verloop WL, Spiering W, Vink EE, Beeftink MM, Blankestijn PJ, Doevendans PA,

Voskuil M. Denervation of the renal arteries in metabolic syndrome: the

DREAMS-study. Hypertension. 2015 Apr;65(4):751-7. doi:

10.1161/HYPERTENSIONAHA.114.04798. Epub 2015 Feb 2. PubMed PMID: 25646297.

 

 

20: Vink EE, Boer A, Verloop WL, Spiering W, Voskuil M, Vonken E, Hoogduin JM,

Leiner T, Bots ML, Blankestijn PJ. The effect of renal denervation on kidney

oxygenation as determined by BOLD MRI in patients with hypertension. Eur Radiol.

2015 Jul;25(7):1984-92. doi: 10.1007/s00330-014-3583-1. Epub 2015 Jan 18. PubMed

PMID: 25595641.

21: Casteleijn NF, Blankestijn PJ, Gansevoort RT. In reply to 'catheter-based

renal denervation in ADPKD: just for pain control?'. Am J Kidney Dis. 2014

Dec;64(6):999-1000. doi: 10.1053/j.ajkd.2014.07.028. Epub 2014 Nov 19. PubMed

PMID: 25453837.

 

 

22: Verloop WL, Agema WR, Allaart CP, Blankestijn PJ, Khan M, Meuwissen M, Muijs

van de Moer WM, Rensing BJ, Spiering W, Voskuil M, Doevendans PA; working group

for renal denervation. Renal denervation for the treatment of hypertension: the

Dutch consensus. Neth J Med. 2014 Nov;72(9):449-54. PubMed PMID: 25431389.

 

 

23: Henry TL, De Brouwer BF, Van Keep MM, Blankestijn PJ, Bots ML, Koffijberg H.

Cost-effectiveness of renal denervation therapy for the treatment of resistant

hypertension in The Netherlands. J Med Econ. 2015 Jan;18(1):76-87. doi:

10.3111/13696998.2014.978453. Epub 2014 Nov 7. PubMed PMID: 25367314.

 

 

24: Henry T, De BB, Van KM, Blankestijn PJ, Bots ML, Koffijberg H. Cost

Effectiveness Of Renal Denervation Therapy For The Treatment Of Resistant

Hypertension In The Netherlands. Value Health. 2014 Nov;17(7):A490. doi:

10.1016/j.jval.2014.08.1445. Epub 2014 Oct 26. PubMed PMID: 27201457.

 

 

25: Verloop WL, Vink EE, Spiering W, Blankestijn PJ, Doevendans PA, Bots ML,

Vonken EJ, Voskuil M, Leiner T. Effects of renal denervation on end organ damage

in hypertensive patients. Eur J Prev Cardiol. 2015 May;22(5):558-67. doi:

10.1177/2047487314556003. Epub 2014 Oct 17. PubMed PMID: 25326543.

 

 

26: Vink EE, Verloop WL, Siddiqi L, van Schelven LJ, Liam Oey P, Blankestijn PJ.

The effect of percutaneous renal denervation on muscle sympathetic nerve activity

in hypertensive patients. Int J Cardiol. 2014 Sep;176(1):8-12. doi:

10.1016/j.ijcard.2014.06.021. Epub 2014 Jun 28. PubMed PMID: 25027168.

 

 

27: Vink EE, Verloop WL, Bost RB, Voskuil M, Spiering W, Vonken EJ, Bots ML,

Blankestijn PJ. The blood pressure-lowering effect of renal denervation is

inversely related to kidney function. J Hypertens. 2014 Oct;32(10):2045-53;

discussion 2053. doi: 10.1097/HJH.0000000000000282. PubMed PMID: 25023158.

 

 

28: Verloop WL, Vink EE, Spiering W, Blankestijn PJ, Doevendans PA, Bots ML,

Vonken EJ, Voskuil M. Renal denervation in multiple renal arteries. Eur J Clin

Invest. 2014 Aug;44(8):728-35. doi: 10.1111/eci.12289. PubMed PMID: 24931208.

 

 

 

29: Blankestijn PJ, Alings M, Voskuil M, Grobbee DE. The complexity after

simplicity: how to proceed with renal denervation in hypertension? Eur J Prev

Cardiol. 2015 Apr;22(4):412-4. doi: 10.1177/2047487314538859. Epub 2014 Jun 9.

PubMed PMID: 24914028.

 

 

 

30: Blankestijn PJ, Bots ML, Spiering W, Leiner T, Voskuil M. Pro: sympathetic

renal denervation in hypertension and in chronic kidney disease. Nephrol Dial

Transplant. 2014 Jun;29(6):1120-3. doi: 10.1093/ndt/gfu099. PubMed PMID:

24876199.

 

 

 

31: Vink EE, Goldschmeding R, Vink A, Weggemans C, Bleijs RL, Blankestijn PJ.

Limited destruction of renal nerves after catheter-based renal denervation:

results of a human case study. Nephrol Dial Transplant. 2014 Aug;29(8):1608-10.

doi: 10.1093/ndt/gfu192. Epub 2014 May 29. PubMed PMID: 24875664.

 

 

 

32: de Beus E, de Jager R, Joles JA, Grassi G, Blankestijn PJ. Sympathetic

activation secondary to chronic kidney disease: therapeutic target for renal

denervation? J Hypertens. 2014 Sep;32(9):1751-61. doi:

10.1097/HJH.0000000000000210. Review. PubMed PMID: 24805954.

 

 

 

33: Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B, Blicher MK, Severino

F, Wuerzner G, Taylor A, Pechère-Bertschi A, Jokhaji F, Fadl Elmula FE, Rosa J,

Czarnecka D, Ehret G, Kahan T, Renkin J, Widimsky J Jr, Jacobs L, Spiering W,

Burnier M, Mark PB, Menne J, Olsen MH, Blankestijn PJ, Kjeldsen S, Bots ML,

Staessen JA; European Network Coordinating research on REnal Denervation

Consortium. Eligibility for renal denervation: experience at 11 European expert

centers. Hypertension. 2014 Jun;63(6):1319-25. doi:

10.1161/HYPERTENSIONAHA.114.03194. Epub 2014 Mar 24. PubMed PMID: 24664290.

34: Vink EE, de Beus E, de Jager RL, Voskuil M, Spiering W, Vonken EJ, de Wit GA,

Roes KC, Bots ML, Blankestijn PJ. The effect of renal denervation added to

standard pharmacologic treatment versus standard pharmacologic treatment alone in

patients with resistant hypertension: rationale and design of the SYMPATHY trial.

Am Heart J. 2014 Mar;167(3):308-314.e3. doi: 10.1016/j.ahj.2013.11.010. Epub 2013

Dec 4. PubMed PMID: 24576513.

 

 

35: Casteleijn NF, de Jager RL, Neeleman MP, Blankestijn PJ, Gansevoort RT.

Chronic kidney pain in autosomal dominant polycystic kidney disease: a case

report of successful treatment by catheter-based renal denervation. Am J Kidney

Dis. 2014 Jun;63(6):1019-21. doi: 10.1053/j.ajkd.2013.12.011. Epub 2014 Feb 8.

PubMed PMID: 24518126.

 

 

36: Koeners MP, Vink EE, Kuijper A, Gadellaa N, Rosenberger C, Mathia S, van den

Meiracker AH, Garrelds IM, Blankestijn PJ, Joles JA. Stabilization of hypoxia

inducible factor-1α ameliorates acute renal neurogenic hypertension. J Hypertens.

2014 Mar;32(3):587-97. doi: 10.1097/HJH.0000000000000060. PubMed PMID: 24309492.

 

 

37: Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Böhm M, Campese VM,

Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia

G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica

DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD.

International expert consensus statement: Percutaneous transluminal renal

denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013

Dec 3;62(22):2031-45. doi: 10.1016/j.jacc.2013.08.1616. Epub 2013 Sep 18. PubMed

PMID: 24021387.

 

 

38: de Jager RL, Blankestijn PJ. Pathophysiology I: the kidney and the

sympathetic nervous system. EuroIntervention. 2013 May;9 Suppl R:R42-7. doi:

10.4244/EIJV9SRA8. Review. PubMed PMID: 23732154.

 

 

39: Hubens LE, Verloop WL, Joles JA, Blankestijn PJ, Voskuil M. Ischemia and

reactive oxygen species in sympathetic hyperactivity states: a vicious cycle that

can be interrupted by renal denervation? Curr Hypertens Rep. 2013

Aug;15(4):313-20. doi: 10.1007/s11906-013-0367-y. Review. PubMed PMID: 23754326.

 

 

40: Verloop WL, Vink EE, Voskuil M, Vonken EJ, Rookmaaker MB, Bots ML, Doevendans

PA, Blankestijn PJ, Spiering W. Eligibility for percutaneous renal denervation:

the importance of a systematic screening. J Hypertens. 2013 Aug;31(8):1662-8.

doi: 10.1097/HJH.0b013e328362152e. PubMed PMID: 23743806.

 

 

41: de Beus E, Blankestijn PJ, Fox JG, Zoccali C. Catheter-based renal

denervation as a novel treatment for loin pain haematuria syndrome. Nephrol Dial

Transplant. 2013 Sep;28(9):2197-9. doi: 10.1093/ndt/gft225. Epub 2013 Jun 5.

PubMed PMID: 23739153.

 

 

42: Vink EE, Bots ML, Blankestijn PJ. Renal denervation as therapy for

hypertension: potentials and unanswered questions. Eur J Prev Cardiol. 2013

Dec;20(6):980-91. doi: 10.1177/2047487312473019. Epub 2012 Dec 19. Review. PubMed

PMID: 23610453.

 

 

43: Vink EE, de Jager RL, Blankestijn PJ. Sympathetic hyperactivity in chronic

kidney disease: pathophysiology and (new) treatment options. Curr Hypertens Rep.

2013 Apr;15(2):95-101. doi: 10.1007/s11906-013-0328-5. Review. PubMed PMID:

23354877.

 

 

44: Persu A, Scavée C, Staessen JA, Blankestijn PJ. Electric nerve stimulation to

monitor the efficacy of renal denervation. Hypertension. 2013 Feb;61(2):288-9.

doi: 10.1161/HYPERTENSIONAHA.111.00389. Epub 2013 Jan 2. PubMed PMID: 23283354.

 

 

45: Vink EE, Blankestijn PJ. Catheter-based renal nerve ablation and centrally

generated sympathetic activity in difficult-to-control hypertensive patients.

Hypertension. 2013 Feb;61(2):e8. doi: 10.1161/HYPERTENSIONAHA.111.00477. Epub

2012 Dec 3. PubMed PMID: 23213193.

 

 

46: Blankestijn PJ, Joles JA. Hypertension: Renal denervation in chronic kidney

disease. Nat Rev Nephrol. 2012 Jul 3;8(8):439-40. doi: 10.1038/nrneph.2012.143.

PubMed PMID: 22751507.

 

 

47: Vink EE, Blankestijn PJ. Evidence and consequences of the central role of the

kidneys in the pathophysiology of sympathetic hyperactivity. Front Physiol. 2012

Feb 20;3:29. doi: 10.3389/fphys.2012.00029. eCollection 2012. PubMed PMID:

22363298; PubMed Central PMCID: PMC3282535.

 

 

48: Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doevendans PA.

Percutaneous renal denervation for the treatment of resistant essential

hypertension; the first Dutch experience. Neth Heart J. 2011 Aug;19(7-8):319-23.

doi: 10.1007/s12471-011-0143-z. PubMed PMID: 21567219; PubMed Central PMCID:

PMC3144331.

 

 

 

49: Blankestijn PJ, Ritz E. Renal denervation: potential impact on hypertension

in kidney disease? Nephrol Dial Transplant. 2011 Sep;26(9):2732-4. doi:

10.1093/ndt/gfr190. Epub 2011 Apr 19. PubMed PMID: 21505095.

 

 

50: Nadery-Siddiqi L, Mali WP, Blankestijn PJ. [Treatment of hypertension by

percutaneous endovascular renal denervation]. Ned Tijdschr Geneeskd.

2010;154:A2165. Dutch. PubMed PMID: 21029485.